Publications
- Effect of clinical parameters on second- and third-line erlotinib treatment of EGFR wild type patients with advanced NSCLC2019 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University, Second Faculty of Medicine
- Optimal procedure in treatments of advanced ALK-positive and ROS1-positive non-small cell lung cancers2019 | Third Faculty of Medicine
- Erlotinib in the first line treatment of the metastatic non-small cell lung cancer2018 | Third Faculty of Medicine
- Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer2023 | Faculty of Medicine in Pilsen, Third Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Durvalumab in the treatment of locally advanced unresectable non‑small cell lung cancer – case report2023 | First Faculty of Medicine, Third Faculty of Medicine
- Treatment with pembrolizumab in a patient with non-small cell lung cancer after a faecal transplantation - case report2023 | First Faculty of Medicine, Third Faculty of Medicine
- Nivolumab in a patient with NSCLC: a protracted but effective treatment full of toxicities - case report2023 | Third Faculty of Medicine
- Immunotherapy in patients with small cell lung cancer, a chance for a longer and quality life - case report2023 | Third Faculty of Medicine
- How many lines of treatment can be given to a patient with non-small cell lung cancer – case report2023 | Third Faculty of Medicine
- Targeted treatment with osimertinib in the adjuvant treatment of a patient with non‐small cell lung cancer – case report2023 | Third Faculty of Medicine
Loading network view...